{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:50:34Z","timestamp":1791186634593,"version":"4.1.0"},"reference-count":55,"publisher":"SAGE Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2015,5,7]]},"DOI":"10.3233\/jad-142421","type":"journal-article","created":{"date-parts":[[2015,5,29]],"date-time":"2015-05-29T05:17:43Z","timestamp":1432876663000},"page":"123-136","source":"Crossref","is-referenced-by-count":40,"title":["Nasal Application of the Galantamine Pro-drug Memogain Slows Down Plaque Deposition and Ameliorates Behavior in 5X Familial Alzheimer\u2019s Disease Mice"],"prefix":"10.1177","volume":"46","author":[{"given":"Soumee","family":"Bhattacharya","sequence":"first","affiliation":[{"name":"Neurogenetics Special Laboratory, Leibniz Institute for Neurobiology, Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Maelicke","sequence":"additional","affiliation":[{"name":"Galantos Pharma GmbH, Nieder-Olm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Montag","sequence":"additional","affiliation":[{"name":"Neurogenetics Special Laboratory, Leibniz Institute for Neurobiology, Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-142421_ref1","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2165\/11591860-000000000-00000","article-title":"Combination therapy for Alzheimer\u2019s disease","volume":"28","author":"Patel","year":"2011","journal-title":"Drugs Aging"},{"key":"10.3233\/JAD-142421_ref2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0006-3223(00)01109-4","article-title":"Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer\u2019s disease","volume":"49","author":"Maelicke","year":"2001","journal-title":"Biol Psychiatry"},{"key":"10.3233\/JAD-142421_ref3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1527-3458.2002.tb00221.x","article-title":"Galantamine - a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer\u2019s disease","volume":"8","author":"Lilienfeld","year":"2002","journal-title":"CNS Drug Rev"},{"key":"10.3233\/JAD-142421_ref4","doi-asserted-by":"crossref","first-page":"216","DOI":"10.2165\/00023210-199402030-00006","article-title":"CNS nicotine receptors. Possible therapeutic targets in neurodegenerative disorders","volume":"2","author":"Court","year":"1994","journal-title":"CNS Drugs"},{"key":"10.3233\/JAD-142421_ref5","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1124\/mol.51.5.776","article-title":"Chronic nicotine treatment up-regulates alpha3 and alpha7 acetylcholine receptor subtypes expressed by the human neuroblastoma cell line SH-SY5Y","volume":"51","author":"Peng","year":"1997","journal-title":"Mol Pharmacol"},{"key":"10.3233\/JAD-142421_ref6","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0006-8993(98)00138-3","article-title":"Stimulation of alpha4beta2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity","volume":"792","author":"Kihara","year":"1998","journal-title":"Brain Res"},{"key":"10.3233\/JAD-142421_ref7","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2165\/00002512-200320100-00006","article-title":"A long-term comparison of galantamine and donepezil in the treatment of Alzheimer\u2019s disease","volume":"20","author":"Wilcock","year":"2003","journal-title":"Drugs Aging"},{"key":"10.3233\/JAD-142421_ref8","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.cbi.2006.11.008","article-title":"Nicotinic component of galantamine in the regulation of amyloid precursor protein processing","volume":"165","author":"Lenzken","year":"2007","journal-title":"Chem Biol Interact"},{"key":"10.3233\/JAD-142421_ref9","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1517\/13543784.16.12.1987","article-title":"An update on the pharmacology of galantamine","volume":"16","author":"Villarroya","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"10.3233\/JAD-142421_ref10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jns.2009.01.024","article-title":"Galantamine inhibits beta-amyloid aggregation and cytotoxicity","volume":"280","author":"Matharu","year":"2009","journal-title":"J Neurol Sci"},{"key":"10.3233\/JAD-142421_ref11","doi-asserted-by":"crossref","first-page":"40180","DOI":"10.1074\/jbc.M110.142356","article-title":"Galantamine induced amyloid-\u03b2 clearance mediated via stimulation of microglial nicotinic acetylcholine receptors","volume":"285","author":"Takata","year":"2010","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-142421_ref12","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2147\/NDT.S24196","article-title":"Galantamine treatment in Alzheimer\u2019s disease: Response and long-term outcome in a routine clinical setting","volume":"7","author":"Wallin","year":"2011","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.3233\/JAD-142421_ref13","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1600-0404.2011.01525.x","article-title":"Galantamine and behavior in Alzheimer disease: Analysis of four trials","volume":"124","author":"Kavanagh","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"10.3233\/JAD-142421_ref14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JAD-2010-101290","article-title":"Long-term effects of galantamine treatment on brain functional activities as measured by PET in Alzheimer\u2019s disease patients","volume":"24","author":"Keller","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-142421_ref15","doi-asserted-by":"crossref","first-page":"89454","DOI":"10.1371\/journal.pone.0089454","article-title":"Galantamine slows down plaque formation and behavioral decline in the 5XFAD mouse model of Alzheimer\u2019s disease","volume":"9","author":"Bhattacharya","year":"2014","journal-title":"PLoS One"},{"key":"10.3233\/JAD-142421_ref16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12031-009-9269-5","article-title":"Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy","volume":"40","author":"Maelicke","year":"2010","journal-title":"J Mol Neurosci"},{"key":"10.3233\/JAD-142421_ref17","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1002\/jps.20389","article-title":"Development of a novel high-concentration galantamine formulation suitable for intranasal delivery","volume":"94","author":"Leonard","year":"2005","journal-title":"J Pharm Sci"},{"issue":"Suppl 3","key":"10.3233\/JAD-142421_ref18","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2202-9-S3-S6","article-title":"Intranasal administration of acetylcholinesterase inhibitors. S","volume":"9","author":"Costantino","year":"2008","journal-title":"BMC Neurosci"},{"key":"10.3233\/JAD-142421_ref19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijpharm.2012.06.057","article-title":"Investigation of formulation factors affecting in vitro and in vivo characteristics of a galantamine transdermal system","volume":"436","author":"Park","year":"2012","journal-title":"Int J Pharm"},{"key":"10.3233\/JAD-142421_ref20","doi-asserted-by":"crossref","first-page":"10129","DOI":"10.1523\/JNEUROSCI.1202-06.2006","article-title":"Intraneuronal \u03b2-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer\u2019s disease mutations: Potential factors in amyloid plaque formation","volume":"26","author":"Oakley","year":"2006","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-142421_ref21","doi-asserted-by":"crossref","first-page":"8898","DOI":"10.1523\/JNEUROSCI.2693-05.2005","article-title":"Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer\u2019s disease","volume":"25","author":"Comery","year":"2005","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-142421_ref22","doi-asserted-by":"crossref","first-page":"5161","DOI":"10.1073\/pnas.0600948103","article-title":"Early onset behavioral and synaptic deficits in a mouse model of Alzheimer\u2019s disease","volume":"103","author":"Jacobsen","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-142421_ref23","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/nm.1872","article-title":"Glutaminyl cyclase inhibition attenuates pyroglutamate A\u03b2 and Alzheimer\u2019s disease-like pathology in vivo","volume":"14","author":"Schilling","year":"2008","journal-title":"Nat Med"},{"key":"10.3233\/JAD-142421_ref24","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1177\/002215540205000403","article-title":"Comparative analysis of an improved thioflavin-s stain, Gallyas silver stain, and immunohistochemistry for neurofibrillary tangle demonstration on the same sections.","volume":"50","author":"Sun","year":"2002","journal-title":"J Histochem Cytochem"},{"key":"10.3233\/JAD-142421_ref25","first-page":"001747","article-title":"Galantamine for Alzheimer\u2019s disease and mild cognitive impairment. CD","author":"Loy","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.3233\/JAD-142421_ref26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1474-4422(08)70261-8","article-title":"Safety and efficacy of galantamine (Reminyl) in severe Alzheimer\u2019s disease (the SERAD study): A randomised, placebo-controlled, double-blind trial","volume":"8","author":"Burns","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-142421_ref27","first-page":"1","article-title":"Galantamine-ER for the treatment of mild-to-moderate Alzheimer\u2019s disease","volume":"5","author":"Seltzer","year":"2010","journal-title":"Clin Interv Aging"},{"key":"10.3233\/JAD-142421_ref28","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/BF03349887","article-title":"Nasal spray vs. oral administration of bromocriptine: pharmacology and effect on serum prolactin in puerperal women","volume":"19","author":"Cicinelli","year":"1996","journal-title":"J Endocrinol Invest"},{"key":"10.3233\/JAD-142421_ref29","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1124\/jpet.301.1.391","article-title":"Intranasal delivery of morphine","volume":"301","author":"Illum","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.3233\/JAD-142421_ref30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2007.03.025","article-title":"Intranasal delivery: Physicochemical and therapeutic aspects","volume":"337","author":"Costantino","year":"2007","journal-title":"Int J Pharm"},{"key":"10.3233\/JAD-142421_ref31","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijpharm.2006.11.013","article-title":"In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo","volume":"335","author":"Kays Leonard","year":"2007","journal-title":"Int J Pharm"},{"key":"10.3233\/JAD-142421_ref32","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/0091-3057(78)90364-7","article-title":"Evidence for a direct cholinergic involvement in the scopolamine-induced amnesia in monkeys: Effects of concurrent administration of physostigmine and methylphenidate with scopolamine","volume":"9","author":"Bartus","year":"1978","journal-title":"Pharmacol Biochem Behav"},{"key":"10.3233\/JAD-142421_ref33","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0926-6410(99)00021-X","article-title":"Scopolamine alters rhesus monkey performance on a novel neuropsychological test battery","volume":"8","author":"Taffe","year":"1999","journal-title":"Brain Res Cogn Brain Res"},{"key":"10.3233\/JAD-142421_ref34","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0014-2999(99)00643-3","article-title":"Effect of rivastigmine on scopolamine-induced memory impairment in rats","volume":"383","author":"Bejar","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"10.3233\/JAD-142421_ref35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbr.2004.05.010","article-title":"Effects of the cholinesterase inhibitors donepezil and metrifonate on scopolamine-induced impairments in the spatial cone field orientation task in rats","volume":"156","author":"van der Staay","year":"2005","journal-title":"Behav Brain Res"},{"key":"10.3233\/JAD-142421_ref36","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s002130050310","article-title":"Enhanced performance of spatial and visual recognition memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys","volume":"131","author":"Rupniak","year":"1997","journal-title":"Psychopharmacology"},{"key":"10.3233\/JAD-142421_ref37","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.pbb.2006.08.007","article-title":"Beneficial effects of galantamine on performance in the object recognition task in Swiss mice: Deficits induced by scopolamine and by prolonging the retention interval","volume":"85","author":"de Bruin","year":"2006","journal-title":"Pharmacol Biochem Behav"},{"key":"10.3233\/JAD-142421_ref38","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0031-9384(01)00524-8","article-title":"Transgenic mouse models of Alzheimer\u2019s disease","volume":"73","author":"Janus","year":"2001","journal-title":"Physiol Behav"},{"key":"10.3233\/JAD-142421_ref39","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/0896-6273(95)90107-8","article-title":"Age-related CNS disorder and early death in transgenic FVB\/N mice overexpressing Alzheimer amyloid precursor proteins","volume":"15","author":"Hsiao","year":"1995","journal-title":"Neuron"},{"key":"10.3233\/JAD-142421_ref40","doi-asserted-by":"crossref","first-page":"6483","DOI":"10.1074\/jbc.274.10.6483","article-title":"Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain","volume":"274","author":"Moechars","year":"1999","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-142421_ref41","doi-asserted-by":"crossref","first-page":"e80706","DOI":"10.1371\/journal.pone.0080706","article-title":"Modeling Alzheimer\u2019s disease in mouse without mutant protein overexpression: Cooperative and Independent effects of A\u03b2 and tau","volume":"8","author":"Guo","year":"2013","journal-title":"PloS One"},{"key":"10.3233\/JAD-142421_ref42","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/089198870101400111","article-title":"Anxiety and Alzheimer\u2019s disease","volume":"14","author":"Ferretti","year":"2001","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"10.3233\/JAD-142421_ref43","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00002093-200401000-00004","article-title":"Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms","volume":"18","author":"Hwang","year":"2004","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.3233\/JAD-142421_ref44","first-page":"180","article-title":"Pharmacological and molecular enhancement of learning in aging and Alzheimer\u2019s disease","volume":"99","author":"Disterhoft","year":"2006","journal-title":"J Physiol"},{"key":"10.3233\/JAD-142421_ref45","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1517\/13543784.8.4.463","article-title":"Metrifonate (Trichlorfon): A review of the pharmacology, pharmacokinetics and clinical experience with a new acetylcholinesterase inhibitor for Alzheimer\u2019s disease","volume":"8","author":"Ringman","year":"1999","journal-title":"Expert Opin Investig Drugs"},{"key":"10.3233\/JAD-142421_ref46","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1073\/pnas.1219731110","article-title":"Cholinergic signaling in the hippocampus regulates social stress resilience andanxiety- and depression- like behavior","volume":"110","author":"Mineur","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-142421_ref47","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1471-2377-14-101","article-title":"Early intervention in Alzheimer\u2019s disease: A health economic study of the effects of diagnostic timing","volume":"14","author":"Barnett","year":"2014","journal-title":"BMC Neurol"},{"key":"10.3233\/JAD-142421_ref48","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2147\/CEOR.S22265","article-title":"Impact of early intervention and disease modifcation in patients with predementia Alzheimer\u2019s disease: A Markov model simulation","volume":"3","author":"Budd","year":"2011","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.3233\/JAD-142421_ref49","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.bmcl.2012.10.111","article-title":"Investigating the binding interactions of galantamine with \u03b2-amyloid peptide","volume":"23","author":"Rao","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.3233\/JAD-142421_ref50","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejmech.2013.09.050","article-title":"Acetylcholinesterase inhibitors as Alzheimer therapy: From nerve toxins to neuroprotection","volume":"70","author":"Singh","year":"2013","journal-title":"Eur J Med Chem"},{"key":"10.3233\/JAD-142421_ref51","doi-asserted-by":"crossref","first-page":"E3825","DOI":"10.1073\/pnas.1410315111","article-title":"Design of donecopride, a dual serotonin subtype 4 receptor agonist\/acetylcholinesterase inhibitor with potential interest for Alzheimer\u2019s disease treatment","volume":"111","author":"Lecoutey","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-142421_ref52","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","article-title":"A plaque-specific antibody clears existing \u03b2-amyloid plaques in Alzheimer\u2019s disease mice","volume":"76","author":"Demattos","year":"2012","journal-title":"Neuron"},{"key":"10.3233\/JAD-142421_ref53","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nature12481","article-title":"Self-propagation of pathogenic protein aggregates in neurodegenerative diseases","volume":"501","author":"Jucker","year":"2013","journal-title":"Nature"},{"key":"10.3233\/JAD-142421_ref54","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1212\/WNL.0b013e318246d67a","article-title":"Accelerated cortical atrophy in cognitively normal elderly with high \u03b2-amyloid deposition","volume":"78","author":"Ch\u00e9telat","year":"2012","journal-title":"Neurology"},{"key":"10.3233\/JAD-142421_ref55","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/ana.22333","article-title":"Amyloid-\u03b2 associated cortical thinning in clinically normal elderly","volume":"69","author":"Becker","year":"2011","journal-title":"Ann Neurol"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-142421","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:02:06Z","timestamp":1777370526000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-142421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,7]]},"references-count":55,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jad-142421","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,7]]}}}